Introduction: Who Should Be Tested and When
Hyperinsulinism most commonly affects newborns and infants, though it can appear later in childhood or even adulthood. Anyone experiencing symptoms of low blood sugar should be evaluated, but the need for diagnostic testing becomes especially urgent in certain situations. Newborns who show signs of hypoglycemia—abnormally low blood sugar—within the first hours or days of life need immediate assessment. This includes babies who are unusually sleepy, feeding poorly, appearing cold or lethargic, or showing pale or bluish skin coloring.[4]
Because low blood sugar symptoms in babies can easily be mistaken for typical newborn behavior, many cases go unrecognized initially. Excessive hunger, irritability, and prolonged sleeping might seem normal, but when combined with other signs, they warrant medical attention. In older children, symptoms become somewhat easier to identify and may include shaking, weakness, confusion, anxiety, or extreme tiredness. If a child experiences these symptoms regularly, especially before meals or after physical activity, diagnostic testing for hyperinsulinism should be considered.[4]
Certain babies face higher risk and should be monitored closely even without obvious symptoms. Infants who experienced stress during birth—such as oxygen deprivation or problems with the placenta—may develop a temporary form of hyperinsulinism. Babies born to mothers with poorly controlled diabetes during pregnancy are also at increased risk. Additionally, children diagnosed with certain genetic syndromes, including Beckwith-Wiedemann syndrome, Kabuki syndrome, Sotos syndrome, or Turner syndrome, should undergo screening for hyperinsulinism as these conditions frequently occur together.[4]
If hyperinsulinism runs in your family, genetic counseling and prenatal testing may be recommended. In some cases, the condition can be detected before birth through amniocentesis—a test where a small amount of fluid surrounding the baby in the womb is analyzed. This advance knowledge allows medical teams to prepare for the baby’s arrival and begin treatment immediately after birth, potentially preventing brain injury.[18]
Classic Diagnostic Methods
Diagnosing hyperinsulinism involves more than simply checking blood sugar levels, though that is where testing typically begins. The diagnosis requires proving that low blood sugar occurs together with inappropriately high insulin levels—a combination that should not happen in a healthy person. When blood sugar drops, insulin production should stop, but in hyperinsulinism, the pancreas continues releasing insulin despite dangerously low glucose levels.[1]
Blood Tests and Laboratory Analysis
The most important diagnostic step is collecting blood samples when the child’s blood sugar is low. This is called a critical sample, and it must be obtained at the exact moment hypoglycemia occurs because testing blood when glucose levels are normal will not reveal the problem. During a hypoglycemic episode, doctors measure several substances in the blood simultaneously, including glucose, insulin, and ketone bodies. Ketone bodies are alternative fuels the body normally produces when blood sugar is low, but hyperinsulinism blocks their production, leaving the brain without any fuel source at all.[7]
In hyperinsulinism, the critical sample typically shows blood glucose below 50 mg/dL alongside measurable insulin levels. In a healthy person, insulin should be undetectable when blood sugar is this low. Additional blood tests during hypoglycemia may reveal low levels of fatty acids and ketones, which confirms that excess insulin is preventing the body from accessing its backup energy stores. Some specialized centers also measure C-peptide, a substance released along with insulin, which helps confirm that insulin is being produced by the pancreas itself rather than being injected from an outside source.[10]
Blood tests alone cannot always distinguish hyperinsulinism from other causes of low blood sugar, so doctors often need to perform additional assessments. They may check hormone levels including cortisol and growth hormone, which help regulate blood sugar. Testing may also include measuring blood ammonia levels, as certain forms of hyperinsulinism cause ammonia to build up. If ammonia is elevated, it suggests a specific genetic type called GDH-HI, where eating protein triggers insulin release and low blood sugar.[7]
Fasting Studies and Provocative Testing
Many children with hyperinsulinism will be asked to undergo a supervised fasting study in the hospital. This controlled test involves withholding food while continuously monitoring blood sugar and other metabolic markers. The medical team carefully watches for hypoglycemia and immediately obtains critical blood samples when it occurs. Healthy infants can typically fast for six hours—essentially skipping one feeding—without their blood sugar dropping dangerously low. Children with hyperinsulinism, however, cannot maintain normal glucose levels during such a fast.[6]
The fasting study also helps determine the severity of the condition. Some children develop hypoglycemia within an hour or two of stopping feeding, indicating very severe hyperinsulinism that will likely require aggressive treatment. Others can fast longer before blood sugar drops, suggesting a milder form that might respond to medication. Before a child is discharged from the hospital after diagnosis, doctors typically perform a shorter fasting study lasting six to eight hours to confirm the child can safely tolerate a missed or inadequate feeding at home.[6]
In older children who can eat regular meals, doctors may use a protein-loading test to diagnose certain forms of hyperinsulinism. The child is given a protein-rich drink or meal, and blood sugar is monitored afterward. In GDH-HI, protein consumption triggers excessive insulin release, causing blood sugar to plummet. This specific response helps identify which genetic mutation is responsible and guides treatment decisions, as children with this form need to follow a low-protein diet.[9]
Genetic Testing
Genetic testing has become a cornerstone of hyperinsulinism diagnosis, as mutations in at least ten different genes can cause the condition. Identifying the specific genetic cause helps predict how the disease will progress, determines which treatments are most likely to work, and provides information about whether siblings might be affected. Blood samples are sent to specialized laboratories where scientists examine the genes known to regulate insulin secretion from pancreatic beta cells—the cells that produce insulin.[7]
The most common genetic causes involve mutations in genes called ABCC8 and KCNJ11, which control potassium channels in beta cells. These channels act like gates that open and close to regulate insulin release. When they malfunction, the gates stay closed and insulin pours out continuously regardless of blood sugar levels. Other genetic mutations affect different parts of the insulin-control system. Mutations in the GLUD1 gene cause the protein-triggered form mentioned earlier, while mutations in GCK, HADH, and other genes affect how beta cells sense and respond to nutrients.[7]
Genetic testing results typically take several weeks to return, but rapid genetic testing is increasingly available at specialized hyperinsulinism centers. Quick results are especially valuable in newborns because the genetic information helps doctors predict whether medication will work or whether surgery will be needed. However, even with advanced testing, about half of hyperinsulinism cases have no identifiable genetic mutation. This suggests additional disease-causing genes remain undiscovered, and research continues to identify them.[12]
Specialized Imaging Studies
One of the most important advances in hyperinsulinism diagnosis has been the development of specialized imaging to determine whether the entire pancreas is affected (called diffuse disease) or whether only a small area is abnormal (called focal disease). This distinction is critical because focal disease can be completely cured by surgically removing the abnormal section of pancreas, while diffuse disease requires lifelong medical management or removal of most of the pancreas.[7]
The imaging test used to identify focal lesions is called an 18F-DOPA PET-CT scan. This specialized scan works by injecting a radioactive substance that is specifically taken up by abnormal beta cells. The substance lights up on the scan, showing doctors exactly where in the pancreas the problem area is located. The scan combines positron emission tomography (PET), which shows metabolic activity, with computed tomography (CT), which provides detailed anatomical pictures. Together, they create a roadmap that surgeons can use to remove only the diseased tissue while leaving healthy pancreas behind.[16]
PET-CT scanning is not universally available and is typically performed only at specialized hyperinsulinism centers. The procedure requires the child to lie still for about 30-60 minutes, so young children usually need sedation or anesthesia. The test involves some radiation exposure, but most experts agree the benefits—potentially curing the disease with limited surgery—far outweigh the small radiation risk. Not all centers have access to this technology, and in some parts of the world, it remains unavailable, making management decisions more difficult.[16]
Continuous Glucose Monitoring
Traditional blood sugar testing requires pricking the finger or drawing blood from a vein multiple times daily, which is painful and provides only snapshots of glucose levels at specific moments. Continuous glucose monitoring systems (CGM) have revolutionized how hyperinsulinism is diagnosed and managed. These small devices are attached to the skin with a tiny sensor that sits just under the surface. The sensor measures glucose in the fluid between cells continuously, day and night, and sends readings to a display device or smartphone every few minutes.[1]
CGM systems allow doctors and parents to see patterns that finger-stick testing might miss. They reveal how blood sugar responds to meals, medications, activity, and sleep. They also detect hypoglycemia that occurs during sleep, when a child cannot report symptoms. Alarms can be set to alert caregivers when blood sugar drops below a certain level, providing an early warning system that helps prevent severe episodes. For children whose hypoglycemia occurs unpredictably, CGM provides reassurance and safety that traditional testing cannot match.[1]
While CGM has greatly improved hyperinsulinism care, it is important to understand that these devices are not perfectly accurate, especially when blood sugar is very low. Most portable glucose meters and CGM systems can be off by as much as 20 percent when measuring glucose below 70 mg/dL. For this reason, any CGM reading indicating low blood sugar should be confirmed with a laboratory test using blood drawn into a special tube containing sodium fluoride, which prevents the blood cells from consuming glucose before the sample is analyzed. Despite this limitation, CGM remains an invaluable tool for day-to-day management and helps reduce the frequency of painful finger sticks.[6]
Diagnostics for Clinical Trial Qualification
Children with hyperinsulinism may be eligible to participate in clinical trials testing new treatments. These research studies require standardized diagnostic criteria to ensure all participants truly have the condition and can be compared fairly. Understanding the testing required for clinical trial enrollment helps families prepare if they are considering this option.
Standard Diagnostic Criteria
Clinical trials for hyperinsulinism typically follow international diagnostic guidelines established by expert consensus. To qualify, patients must have documented hypoglycemia—usually defined as blood glucose below 60 mg/dL on multiple occasions—along with laboratory evidence of excessive insulin during those episodes. The critical blood sample obtained during hypoglycemia must show detectable insulin and C-peptide when these should be suppressed. Low ketone bodies and low free fatty acids at the time of hypoglycemia provide additional confirmation.[10]
Most clinical trials require that hyperinsulinism be confirmed as the primary cause of hypoglycemia by excluding other possibilities. This means testing must rule out other conditions that can cause low blood sugar, such as cortisol deficiency, growth hormone deficiency, certain metabolic disorders, and medication effects. Comprehensive metabolic screening and hormone testing are typically performed to meet these requirements. Some trials accept only genetic forms of hyperinsulinism, requiring participants to have an identified mutation in one of the known disease-causing genes.[10]
Imaging Requirements
Many clinical trials, particularly those testing new medications, require an 18F-DOPA PET-CT scan to classify the disease as focal or diffuse. This imaging must be performed at a certified center using standardized protocols to ensure quality and consistency. The scan results help researchers understand whether treatments work differently for focal versus diffuse disease and may be used to select which patients are most likely to benefit from a particular therapy. Trials focusing on surgical techniques may have even more specific imaging requirements, including detailed anatomical mapping of the pancreas.[16]
Functional Testing
Clinical trials often require standardized fasting studies following specific protocols. These controlled tests measure how long a child can fast safely before developing hypoglycemia and how quickly blood sugar drops once feeding stops. The fasting study provides objective measurement of disease severity, which helps researchers determine if a treatment is working by comparing pre-treatment and post-treatment fasting tolerance. Some trials require multiple fasting studies over time to document changes in disease activity.[10]
Medication trials may also require a glucose infusion rate test. This measures how much sugar must be given intravenously to keep blood glucose normal. Children with severe hyperinsulinism may require glucose infusion rates of 20-30 milligrams per kilogram per minute—three to four times higher than the body’s normal glucose production rate. Reduction in the glucose infusion rate needed to maintain normal blood sugar serves as an objective measure of treatment effectiveness in clinical trials.[6]
Quality of Life and Development Assessments
Because preventing brain damage is the ultimate goal of hyperinsulinism treatment, many clinical trials include neurodevelopmental testing and quality of life assessments. Children may undergo cognitive testing, motor skills evaluation, and behavioral assessments at the beginning and end of the trial. Parents often complete questionnaires about their child’s development, daily functioning, and overall wellbeing. These measures help researchers understand whether new treatments not only control blood sugar but also result in better long-term outcomes for children living with hyperinsulinism.[1]
Some research studies focus specifically on understanding the relationship between hypoglycemia exposure and brain injury. These trials may include specialized brain imaging such as MRI scans to look for subtle changes in brain structure or function. Electroencephalograms (EEG) to measure brain electrical activity might be performed, especially in children who have had seizures. While these tests are primarily research tools rather than standard clinical care, they contribute to better understanding of how to protect children’s brains from hypoglycemia-related damage.[1]





